Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENGOT-OV42 / NSGO-AVATAR: A Three-arm Randomized Study to Evaluate the Efficacy of Niraparib-bevacizumab-dostarlimab Triplet Combination Against Niraparib-bevacizumab Doublet Combination and Against Standard of Care Therapy in Women With Relapsed Ovarian Cancer Where Platinum Combination Therapy is an Option.

NCT03806049 is registered in ClinicalTrials.gov with Nordic Society of Gynaecological Oncology - Clinical Trials Unit as lead sponsor.

NCT NCT03806049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03806049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENGOT-OV42 / NSGO-AVATAR: A Three-arm Randomized Study to Evaluate the Efficacy of Niraparib-bevacizumab-dostarlimab Triplet Combination Against Niraparib-bevacizumab Doublet Combination and Against Standard of Care Therapy in Women With Relapsed Ovarian Cancer Where Platinum Combination Therapy is an Option.
Lead sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase
Phase 3
Overall status
Withdrawn
Start date
December 31, 2019
Completion date
December 31, 2024
Enrollment
0 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer